CD14 and Sepsis: In a polymicrobial sepsis mouse model, the C5 or CD14 inhibition monotherapy strongly reduced the overall inflammation but failed to increase the survival rates, whereas the combined inhibition therapy significantly reduced the inflammation and increased the survival (22), hence proving its therapeutic advantage.